Understanding Mounjaro: How Many Injections Are in a Mounjaro Pen?

Last reviewed: July 16, 2026

Last updated: July 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) comes in pre-filled pens designed to deliver one dose per week for four consecutive weeks before requiring a refill. Each pen is engineered as a single-use device that dispenses a fixed amount of the GLP-1 and GIP receptor agonist, making it convenient for patients following the standard weekly injection protocol used in clinical trials.

What's Inside a Mounjaro Pen: Injection Count and Design

A standard Mounjaro pen contains enough tirzepatide solution to deliver four separate weekly injections. The pen is labeled with a dose level (0.25 mg, 0.5 mg, 1 mg, 2.5 mg, or 5 mg), and each injection from that pen delivers the same dose. Patients typically begin at the lowest dose and escalate weekly or every few weeks as directed by their healthcare provider.

The pen mechanism includes a dose-selection dial and a plunger system that meters out precise amounts with each use. After delivering four doses, the pen is considered empty and must be replaced. PlexusDx sources tirzepatide injection from licensed 503A compounding pharmacies, offering flexible dosing and refill schedules tailored to individual treatment plans.

Mounjaro pens are single-patient-use devices, meaning they cannot be shared even if medication remains. The pen design prioritizes safety and accuracy, though some patients find the weekly cadence requires significant calendar management over months of treatment.

Understanding Mounjaro Dosing Escalation and Pen Refills

Mounjaro follows a tiered escalation schedule in most clinical protocols: week one begins at 0.25 mg, week two increases to 0.5 mg, week three moves to 1 mg, and week four reaches 2.5 mg. Many patients then advance to the 5 mg maintenance dose in subsequent weeks. Each dose level requires its own pen, meaning a single patient may use multiple pens during the titration phase alone.

The escalation approach reduces gastrointestinal side effects during the initiation period by allowing the body to acclimate to the medication. However, purchasing separate pens for each dose tier can become costly, especially without insurance coverage. PlexusDx compounded tirzepatide injection eliminates the multi-pen burden by offering personalized dosing at one flat monthly rate ($289/mo), regardless of whether a patient is at 0.25 mg or 5 mg.

Once patients stabilize at a maintenance dose, they continue refilling that specific strength pen monthly. The predictable four-injection cycle per pen makes it straightforward to track refill timing, though patients must plan ahead to avoid running out during weekends or holidays.

Cost and Access: Mounjaro Pens vs. Compounded Tirzepatide

Brand-name Mounjaro pens typically cost $1,000 to $1,350 per pen without insurance, creating substantial out-of-pocket expenses during the escalation phase when multiple pens are used. Insurance coverage varies significantly by plan, and many weight-loss treatments remain excluded from coverage entirely. Uninsured patients paying cash face cumulative costs in the thousands within their first months of therapy.

PlexusDx tirzepatide injection is $289/mo month-to-month, or from $249/mo on the 6-month plan from licensed 503A compounding pharmacies and remains flat regardless of dose level—a transparent alternative to pen-based pricing that scales with manufacturer recommendations. The platform serves all 50 states, requires no insurance, and accepts HSA and FSA funds, making it accessible to patients seeking affordable GLP-1 therapy without prior authorization delays.

Compounded medications undergo the same quality and sterility standards as brand products and are prepared by licensed pharmacists. For patients committed to tirzepatide treatment beyond the initial trial phase, compounded delivery often reduces total cost of care by 60–80% while maintaining clinical efficacy and safety.

Personalized Tirzepatide Therapy: The Role of Genetic Testing

Not every patient responds equally to tirzepatide, and genetic variation in peptide pathways can influence efficacy and tolerability. The GLP1R receptor gene (rs6923761), MC4R pathway variants (rs17782313), and FTO genetic markers (rs9939609) are known to modulate weight-loss outcomes in GLP-1 and GIP-based therapies. Understanding individual genetic predispositions helps clinicians optimize dosing strategy and medication selection.

PlexusDx Precision Peptide Genetic Test ($99 add-on after the first month of treatment) maps 14 metabolic pathways, 49 peptides, and 150+ genetic insights to guide therapy personalization. The test is distinct from pharmacogenomic testing—it focuses on peptide-pathway biology rather than drug metabolism—and empowers patients and providers to make data-informed decisions about escalation timing, combination therapy, or alternative GLP-1 compounds.

Patients beginning tirzepatide can start treatment immediately while genetic insights inform fine-tuning in weeks four through eight, aligning testing with the standard dose-escalation window. This approach combines the speed of same-month treatment initiation with precision medicine principles, reducing trial-and-error adjustments and improving long-term adherence.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many doses does one Mounjaro pen contain?

One Mounjaro pen contains four weekly injections. Each pen is labeled with a specific dose strength, and patients use one pen per week for four weeks before needing a refill. During escalation phases, patients may use multiple pens at different dose levels.

Why does Mounjaro require multiple pens during treatment?

Mounjaro dosing follows a weekly escalation schedule to minimize side effects: 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, then maintenance at 5 mg. Each dose level comes in a separate pen, so patients use one pen per week and switch to the next strength when their provider advises escalation.

How does PlexusDx tirzepatide injection pricing compare to brand Mounjaro pens?

Brand Mounjaro pens cost $1,000–$1,350 each without insurance, and escalation phases require multiple pens, totaling thousands monthly. PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) flat, with no flat per-compound pricing increases, no insurance required, and coverage for all 50 states.

Are there safety differences between Mounjaro pens and compounded tirzepatide?

Both are formulated to the same clinical standards. PlexusDx sources tirzepatide from licensed 503A compounding pharmacies, which operate under identical FDA regulatory oversight and quality requirements as brand manufacturers. Efficacy and side-effect profiles are equivalent.

Can the Precision Peptide Genetic Test help me decide between GLP-1 and tirzepatide?

Yes. The PlexusDx Precision Peptide Genetic Test analyzes your GLP1R, GIPR, MC4R, and FTO genetic variants, which influence response to both GLP-1 and dual GLP-1/GIP compounds like tirzepatide. The test provides 150+ insights across 14 peptide pathways, enabling your provider to recommend the therapy best suited to your biology.

Related Reading

• Mounjaro Injections
• Weight Loss Injections Mounjaro
• Hers Mounjaro
• Hims Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.